Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/146943
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTejedor Estrada, Elisenda-
dc.date.accessioned2019-12-18T14:37:00Z-
dc.date.available2019-12-18T14:37:00Z-
dc.date.issued2019-11-
dc.identifier.urihttps://hdl.handle.net/2445/146943-
dc.descriptionPremis Pharmanews-Fedefarma 2019ca
dc.description.abstractA few months ago, a promising study about Alzheimer Disease (AD), a type of dementia, was published in JACC (Journal of the American College of Cardiology). Dementia affects around 50 million people worldwide and around 60-70% of them suffer AD. It is estimated that in 2050 there will be more than 115 million people diagnosed (WHO, 2019). Dementia is a disease that damages cognitive capacity interfering in daily activities. AD is a progressive dementia that worsens through time and lasts around 10-12 years, when the patient dies due to infections or other organic failure...ca
dc.format.extent4 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoengca
dc.rightscc-by-nc-nd (c) Tejedor Estrada, 2019-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourcePremis Fedefarma: Concòrdia / Pharmanews (Facultat de Farmàcia i Ciències de l'Alimentació)-
dc.subject.classificationMalaltia d'Alzheimercat
dc.subject.classificationMalalties neurodegenerativescat
dc.subject.otherAlzheimer's diseaseeng
dc.subject.otherNeurodegenerative Diseaseseng
dc.titleNew approaches to treat Alzheimer Diseaseca
dc.typeinfo:eu-repo/semantics/bachelorThesisca
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
Appears in Collections:Premis Fedefarma: Concòrdia / Pharmanews (Facultat de Farmàcia i Ciències de l'Alimentació)

Files in This Item:
File Description SizeFormat 
3-Elisenda Tejedor Estrada-New approaches to treat Alzheimer Disease.pdf117.53 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons